Connect public, paid and private patent data with Google Patents Public Datasets

Annealed polyvinyl alcohol contact lens

Info

Publication number
CA1222357A
CA1222357A CA 426833 CA426833A CA1222357A CA 1222357 A CA1222357 A CA 1222357A CA 426833 CA426833 CA 426833 CA 426833 A CA426833 A CA 426833A CA 1222357 A CA1222357 A CA 1222357A
Authority
CA
Grant status
Grant
Patent type
Prior art keywords
alcohol
polyvinyl
lens
annealed
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA 426833
Other languages
French (fr)
Inventor
Ping I. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
CIBA-GEIGY INVESTMENTS LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • GPHYSICS
    • G02OPTICS
    • G02CSPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00Optical parts
    • G02C7/02Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04Contact lenses for the eyes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE, IN GENERAL
    • B29DPRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00Producing optical elements, e.g. lenses or prisms
    • B29D11/00009Production of simple or compound lenses
    • B29D11/00038Production of contact lenses
    • B29D11/00076Production of contact lenses enabling passage of fluids, e.g. oxygen, tears, between the area under the lens and the lens exterior
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS, OR APPARATUS
    • G02B1/00Optical elements characterised by the material of which they are made
    • G02B1/04Optical elements characterised by the material of which they are made made of organic materials, e.g. plastics
    • G02B1/041Lenses
    • G02B1/043Contact lenses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S525/00Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S525/937Utility as body contact e.g. implant, contact lens or I.U.D.

Abstract

ANNEALED POLYVINYL ALCOHOL CONTACT LENS

Abstract of the Disclosure Optically clear soft contact lenses of aqueous swollen solid polyvinyl alcohol having a weight average molecular weight of at least 6,000, having been annealed under crystallinity promoting conditions to effectively increase the elastic modulus of the swollen lenses, and optionally subsequently crosslinked, and methods of preparation and the use thereof are disclosed. The lenses are characterized by their relatively high oxygen trans-missibility, sufficient to meet the needs of the human cornea, high optical clarity, improved hot water resistance and superior mechanical properties.

Description

23~;'7 ANN~AL~D POLYVINYL ALCOHOL CONTACT LENS
. .

This invention relates to soft contact lenses made of thermally annealed polyvinyl alcohol.

In general~ existing aqueous swollen soft contact lens materials based on polymers of HE~A, also known as hydroxyethyl methacrylate or as ethylene glycol monomethacrylate7 suffer from either weak mechanical strength, low dissolved oxygen permeability or a combination of both. Moreover, aqueous swollen soft contact lenses of crosslinked HEMA with one or more optional comonomers are known, QS described in U.S. Patent Nos. 2,976,576, 3,841,985 and 3,985,697.
Such hydrogel polymers also suffer from either weak mechanical strength, insufficient dissolved oxygen permeability or a combination thereof. Efforts to increase oxygen permeability by increasing the water content of the hydrogels result in a further decline in the mechanical strength of the lens materials to such an extent that they are extremely fragiIe.

Also, a polyvinyl alcohol crosslinked with glyoxal has been proposed as a contact lens material in U.S. Patent No. 3,408,429. ~ow-ever, no disclosure of polyvinyl alcohol molecular weight, and no specifics concerning the amount of water present in the crosslinking step are disclosed. Additionally, there is no disclosure of annealing under crystallinity promoting conditions.

Furthermore, polyvinyl alcohol films and gels have been reported as opthalmic inserts in the lower conjunctival sac when imbibed with antibiotics such as tetracycline, pilocarpine, atropine 3~

and the like. Such materials are either in the form of a crosslinked film or as a water soluble viscous solution or gel. Sees for example, Y.F. Maichuk, Ophthalmic Drug Inserts~ Invest. Ophthalmol., Vol. 14, pages 87-90 (1975)j D.W. Lamberts, Solid Delivery Devicess Int. Ophthalmol. Clinic, Vol. 20, No. 3, pages 68-69 (1980) and Y.F. Maichuk, Antibiotik, Vol. 12, No. 4, pages 43 2-5 (1967).

It is an object of the present invention to provide soft contact lenses obviating or substantially reducing the afore-mentioned drawbacks associated with the prior art.

It is a further object of the present in~ention to provide soft contact lenses comprising polyvinyl alcohol which has been annealed under crystallinity promoting conditions such that the annealed aqueous swollen lenses are substantially insoluble in the ocular tear environment, possess a high water content, an oxygen t.rans-missibility in excess of that necessary to meet the needs of the human cornea, improved hot water resistance and superior mechanical properties.

It is a further object of the invention to provide, sirnple, low cost processes for the preparation of such lenses.

It is a further object of the invention to provide a method of correcting vision in patients in need of the same by wearing such a lens on the surface of the cornea.

It is a further object of the invention to provide a method of cosmetic enhancement of the eye of a patient by wearing such a lens, which has been suitably tinted to si~ulate the iris of desired color, on the surface of the cornea.

~ %~23!~7 Accordingly, the present invention provides optically clear soft contact lenses of swollen solid polyvinyl alcohol having a weight average molecular weight of at least about 6,000, which has been annealed under crystallinity promoting conditions to a crystallinity degree between 0.195 to 0.7, swollen in a suitablP solvent and optionally subsequently sparingly crosslinked with a tetravalent metal salt or complex or an organic polyfunctional crosslinking agent, the resultant annealed, and optionally crosslinked, swollen lens possessing an oxygen transmissibility capabil:ity in an aqueous environment in excess of that necessary to meet the needs of the human cornea.

Preferably, the polyvinyl alcohol has a weight average molecular ~eight of at least about 10,000.

As an upper limit, the polyvinyl alcohol may have a weight average molecular weight of up to 1,000,000. Preferably, the polyvinyl alcohol has a weight average molecular weight of up to 300,000.

Polyvinyl alcohol is ordinarily prepared by hydrolysis of the corresponding polyvinyl acetate. In a preferred embodiment, the polyvinyl alcohol contains less than 1 mole % of the polyvinyl acetate units.

Ordinarily, polyvinyl alcohol predominately possesses a poly(2-hydroxy)ethylene structure. However, the polyvinyl alcohol starting material may also contain a minor amount of hydroxyl groups in the form of 1,2-glycols, such as copolymer units of 1,2-dihydroxy-ethylene in the chain, obtained for example, by alkaline hydrolysis of vinyl acetate-vinylene carbonate copolymers. Advantageously, such a copolymer contains less than 20 mole ~ of such units, preferably less than 10 mole ~ of such units, related to the copolymer.

Moreover, the polyvinyl alcohol may contain minor amounts of copolymer UllitS of ethylene, propylene, acrylamide, methacrylamide, dimethacrylamide, hydroxyethylmethacrylate, methyl methacryla~e, methyl acrylate, ethyl acrylate, vinyl pyrrolidone, hydroxyethyl-acrylate, allyl alcohol, and the like. Preferably, the polymer should contain not more than 5 mole % of units other than those of vinyl alcohol. Most preferably, the polyvinyl alcohol contains less than 1 mole % of such copolymer units.

Commercial polyvinyl alcohol resin may be used, such as ELVANOL
71-30 ~ manufactured by DuPont, or Vinol 125 ~ manufactured by Air Products, Inc.

Preferably, the polyvinyl alcohol to be annealed is substantially insoluble in water up to 50C, most preferably up to 60C.

While such preferred polyvinyl alcohol resins are not soluble in water, they are water swellable, preferably to an extent of at least 50 % by weight water at e~uilibrium, at 25C. The polyvinyl alcohol to be annealed is ordinarily in the form of a shape re-taining mass and may be in the form of a sheet, block, rod, disk, contact lens replica or plasticized shape retaining mass. The polyvinyl alcohol to be annealed should advantageously contain less than 20 % by weight water, preferably not more than 15 % by weight water, since for example under elevated temperature conditions, the polyvinyl alcohol may tend to dissolve in the residual water present. Moreover, when excess water is present the advantageous increase in crystallinity cannot be ordinarily obtained.

The polyvinyl alcohol to be annealed may contain up to 80 % by weight of non-aqueous plasticizer. Preferred plasticizers include polyols, such as ethylene glycol, propylene glycol, and glycerol, amines, such as pyridine, trimethylamine and ethanolamine, ethers, such as ethylene glycol mono- and di-methyl ether, or tetrahydro-furan, formamide, dimethylformamide, dimethylsulfoxide, or ~L2~:357 ~ 5 --plast;ciæer salts such as sodium thiocyanate, ammonium thiocyanate, ethanolamine salts, including triethanolamine acetate and triethanol-amine hydrochloride, and the like. The maximum amount of plasticizer present for optimum results will depend upon the nature of the plasticizer and the annealing conditions for a given polyvinyl alcohol material. A substantial excess of plasticizer under elevated temperature conditions, such as may be present in thermal annealing, may result in phase separa~ion of the plasticizer as the polyvinyl alcohol is annealed and is thus to be avoided. Preferably, the amount of plasticizer should not generally exceed 70 % by weight of the plasticizer plus polyvinyl alcohol to be thermally annealed.

Annealing of the polyvinyl alcohol increases the degree of crystallinity, in term of weight fraction of the crystalline region in the polyvinyl alcohol. This is accompanied by a decrease in its equilibrium water content when subsequently swollen. ~s a result of the increase o the weight fraction of the crystalline region, significant improvements in the mechanical properties oE the resin and in its hot water resistance are obtained.

The degree of crystallinity, in terms of the weight fraction of crystalline material present in the dry polymer, is calculated according to the density technique set forth in A.Packter and M.S.
Nerurkar, ~uropean Polymer JournalJ Vol. 4, pages 685- 693 (1968), where the density of 100 percent of crystalline polymer is taken to be 1.340 and the density of 100 percent amorphous polymer is taken to be 1.270 for polyvinyl alcohol as determined by H. Tadokoro, Bull. Chem. Soc. Japan, Vol. 27 P. 451 (1954); Vol. 28, p. 599 (1955~.

The polyvinyl alcohol resin may be annealed unter crystallinity promoting conditions by various techniques. One method is to carefully evaporate an aqueous or aqueous/plasticizer containing polyvinyl alcohol gel in accordance with the technique set forth in the A. Packter and M.S. Nerurkar article, mentioned before.

3L~2~

Another method of annealing is by stress induced crystallization in the solid state such as by high pressure compression techniques, for example at about 3447 kPa Eor an extended period of time, or correspondingly higher pressures for reduced periods of time.

Preferably, however, the polyvinyl alcohol is in the form of a shape retaining optionally plasticized mass and is thermally annealed, optionally at superatmospheric pressure, by heat treatment until the desired degree of crystallinity is obtained. In thermal annealing the temperature range is advantageously between about 45C and about 200C, preferably between about 50~C and 150~C
and most preferably.between 75~C.and'125C. The polyvinyl alcohol advantageously contains less than 20 % by weight water, preferably not more than 15 % by weight water, most preferably less than 10 % by weight water.

The annealing time for thermal annealing will, of course, vary depending upon the degree of crystallinity.desired and the temperature range utilized, but will preferably range between about 0.1 minute and about 180 minutes, most preferably.between about 1 minute and about 120 minutes, under atmospheric pressure, and correspondingly shorter periods of ti~e under superatmospheric pressure conditions.

The thermal annealing can be conducted in an inert gas, such as nitrogen, helium or the like, or in ambient air. Preferably, the atmosphere is air with a relative humidity of less than 50 %.

Independent of the annealing technique utilized, the extent of annealing should be sufficient to increase the crystallinity, and thus the elastic modulus of the polyvinyl alcohol, as compared to the untreated polyvinyl alcohol starting material. The optimum amount of annealing required to increase the crystallinity to the extent desired, will, of course, vary to some degree depending ~2~35~

on the tacticity and molecular weight distribution of the polyvinyl alcohol The optimum amount of crystallinity of any given polyvinyl alcohol mass can be easily deeermined by varying the annealing conditions, such as annealing temperature and time in thermal annealing, and plotting the resulting elastic modulus and dissolved oxygen permeability, respectively, versus the amount of crystallinity in the weight fraction.

Ordinarily, polyvinyl alcohol which has not been annealed by special treatment has a degree of crystallinity below 0.187 wherein ~he degree of crystallinity is that weight fraction of the crystalline region present in the total weight of polyvinyl alcohol. After annealing, the polyvinyl alcohol advantageously has a degree of crystallinity between about 0.195 and 0.70, preferably between 0.22 and 0.60, and most preferably between 0.30 and 0.50. Advantageously, the corresponding water swollen annealed material in the substantial absence of plasticizer possesses a refractive index of between about I.360 to 1.520, preferably between about 1.365 and 1.490, most preferably between about 1.390 to 1.465. Excessive annealing, e.g. resulting in a degree of crystallinity above 0.70, is undesirable as the oxygen permeability is substantially adversely affected. Moreover such excessively annealed materials also exhibit substantially reduced swelling characteristics7 as well as a loss of flexability in the swollen product.

Subsequent to annealing, the polyvinyl alcohol may be swollen with a swelling solvent to form a substantially shape retaining gel and optionally crosslinked in the partially to fully swollen state (i.e. equilibrium swollen state) with a chemical crosslinking agent in an amount to further increase elastic modulus thereof while maintaining the requisite optical clarity and sufficient ~2~3~7 dissolved oxygen transmissibility of the polyvinyl alcohol swollen lens final product to meet the oxygen demand. Useful crosslinking agents include formaldehyde, aliphatic or aroma~ic dialdehydes such as glutaraldehyde, terephthalaldehyde, ~ dialdehyde poly-vinyl alcohol, and ~he like; aliphatic or aromatic reactive methy].olated polyamines and methylolated polyamides, such as di-methylolurea, dimethylolethylene urea, and trimethylolmelamine;
glyoxal; oxalic acid; polyacrolein, divinyl compounds such as divinyl sulfone and compounds containing vinyl sulfone precursors as end groups, such as ~-sulfatoethylsulfonyl and ~-hydroxyethylsulfonyl, as well as reactive derivatives thereof; triazine derivatives such as 2,4,6-trichloro 1~3,5-triazine and compounds containing chlorinated triazine end groups, as well as reactive derivatives thereof; polyhydroxylated phenolic compounds such as dihydroxy diphenyl sulfone, dihydroxybenzenes, such as resorcinal, and pyrogallol, aliphatic and aromatic polyepoxides such as 1,2,3,4-diepoxybutane and 1,2,7,8-diepoxyoctane; aliphatic and aromatic diisocyanates such as ethylene diisocyanate, 1,2-diisocyanato-propane, 1,3-diisocyanatopropane,.2,4- and 2,6-tolylene diiso-cyanate and hexamethylene diisocyanate; tetravalent borates, including alkali.metal and alkaline earth metal borates, ammonium borates and amine borates, such as ammonium borate, calcium borate, sodium metaborate and sodium tetraborate and methyl-ammonium hydrogen tetraborate; aqueous solutions of boric acid where the pH is adjusted to greater than 7; and tetravalent metal salts, including tetravalent metal salts of æirconium, vanadium, titanium and chromium, such as titanium sulfate, zirconium chloride, vanadyl sulfate, chromic nitrate and organic titanates. Thus, any conventional substantially non-opacifying chemical cross-linking agent for polyvinyl alcohol, capable of forming covalent bonds between itself and the polyvinyl alcohol in a suitable swelling solvent may be used.

Suitable swelling solvents, depending upon the crosslinking agent ~2~:~35~

used, include water, glycerol, ethylene glycol, propylene glycol, acetamide, formamide, ethanolacetamide, dimethylacetamide, ethanol-formamide, dimethylformamide, dimethyl sulfoxide, ethanolamine9 diethylene triamine, triethylene diamine, triethylene tetramine and piperazine~ The swelling solvent chosen should be substantially non-reactive with the crosslinking agent chosen so as not to interfere with the crosslinking reaction of the swollen annealed polyvinyl alcohol substantially shape retaining mass.

Preferably, the annealed polyvinyl alcohol is swollen and treated with an aqueous solution of a borate crosslinking agent at a pH
of greater than 7.

It is a crucial aspect oE the instant invention that any crosslinking operation on the at least partially swollen polyvinyl alcohol be performed subsequent to the annealing operation.

It has been found that the annealing step is easily controllable, to obtain the desired degree of crystallinity while obtaining a product having acceptable oxygen permeability characteristics in meeting the needs of the human cornea and desirable swellability characteristics, if the optional crosslinking operation is performed subsequent to the annealing step.

Where the polyvinyl alcohol is first crosslinked, however, and then the annealing step is performed, the product produced is unsatisfactory. This is believed to be partly due to the crosslinking agent Ereezing the polymer network into a less flexible lattice, and partly due to the crosslinking agent effectively reducing the uninterrupted chain length of the polyvinyl alcohol strands. It is the relatively long chain lengths of polyvinyl alcohol coupled with its relatively mobile s~ate on a molecular level which is believed to contribute to the relative ~2;~3~;~

-- 10 ~

ease of controlled formation bf crystallites during the annealing process. Therefore, necessarily more severe conditions are needed to substantially increase the crystallinity of crosslinked polyvinyl alcohol, if possible at all, as compared to non-crosslinked polyvinyl alcohol. Accordingly, when attempting to increase the crystallinity of crosslinked polyvinyl alcohol, the resulting annealed product possessed multiple adverse characteristics, including substantially impaired water retention, or swellability,substantially reduced oxygen permeability characteristics, to the extent that sufficiently pre-crosslinked subsequent annealed material has an oxygen permeability totally insufficient to meet the needs of the human cornea, and the tendency to be relatively weak in mechanical strength.
Moreover, due to the more extreme conditions necessary to achieve increased crystallinity, the annealing step is correspondingly less controllable.

Furthermore, when crosslinking with a chemical crosslin ing agent, the polyvinyl alcohol must first be swollen, and after crosslinking has occurred, then dried to achieve anneaiing. This not only requires an additional sweliing step, but also increases the likelihood of deformation, e.g. where the polyvinyl alcohol is in the form of a contact lens replica. Also, during annealing of the dried crosslinked material, the polyvinyl alcohol crosslinked network tends to collapse, resulting in a substantially irreversible decrease in swelling and reduction of oxygen permeability.

When crosslinking the polyvinyl alcohol in the partially fo fully swollen state with a chemical crosslinking agent, subsequent to annealing, between about 0.001 and 10 weight percent of cross-linking agent may be used, based on the weight of polyvinyl alcohol present.

3~

The crosslinking of the annealed polyvinyl alcohol swollen mass tends to freeze tne resulting polymer network in place, furthering increasing the mechanical properties of the product.

Where the annealed polyvinyl alcohol is crosslinked with a borate salt in aqueous solution, the nature of the cation moiety is not critical. For purposes of convenience, however, it ;s preferred that the cation be a pharmaceutically acceptable cation. This obviates a washing step wherein the cross]inked material is washed with a pharmaceutically acceptable base, or salt, to remove the undesired cation.

While not limiting to the precise reaction mechanism by which crosslinklng of the polyvinyl alcohol by a borate takes place at a pH greater than 7, it is believed that didiol complex formation occurs between ad~acent molecules of polyvinyl alcohol. Under acid conditions, i.e., where the pH is below 79 onle the non-cross-linked monodiol complex is believed to be formed. Thus, for example, boric acid can be added to polyvinyl alcohol, e.g. in a melt stage or in aqueous solution to polyvinyl alcohol prior to annealing and the non-crosslinked boric acid containing polyvinyl alcohol can be annealed, and subsequently crosslinked by swelling with a suitable swelling solvent, such as water to which there is then added a base to convert the polyvinyl alcohoL/boric acid mass to the swollen crosslinked product.

W~lere the annealed polyvinyl alcohol is to be crosslinked with a borate, any reactive plasticizer, such as a polyol plasticizer including propylene glycol, ethylen glycol or glycerol should advantageously be removed, e.g. by washing the annealed polyvinyl alcohol mass with water, prior to crosslinking.

The amount of borate present in the crosslinked polyvinyl alcohol, ~2~;235ii~7 in terms of milligrams of complexed boron per gram of polyvinyl alcohol, is advantageously between about 0.5 and 50, preferably between about 2 and 35, most preferably between about 5 and 25.

The amount of boron present in the crosslinked polyvinyl alcohol should be sufficient to increase the elastic modulus of the crosslinked material compared to the uncrosslinked annealed polyvinyl alcohol starting material. The optimum amount of boron present to substantially increase the elasticity modulus will, of course, vary to some extent depending upon the molecular weight distribution and the swellability of the polyvinyl alcohol in water.
The optimum amount of boron in any given polyvinyl alcohol substrate can be easily determined by varying the amount of boron present in annealed polyvinyl alcohol samples and plotting the ratio of boron in milligrams to grams of polyvinyl alcohol versus the elastic modulus in kilograms per square centimeter.

A substantial excess of crosslinked boron or other crosslinking agent in the polyvinyl alcohol substrate is ordinarily undesirable, to the extent it may adversely affect the elasticity modulus of the annealed polyvinyl alcohol.

The optionally crosslinked annealed contact lenses according to the instant invention possess higher oxygen permeability in comparisong for example, with poly-hydroxyethylmethacrylate.

Similarly, the tensile strength of the optionally crosslinked annealed contact lenses according to the instant invention is far superior to that of poly-hydroxyethylmethacrylate.

It is important to note that the dissolved oxygen permeability, DK, is an intrinsic property of the contact lens material only, whereas the dissolved oxygen transmissibility, DK/L, describes - 13 ~

the actuyl flux of oxygen per unit oxygen tension (partial pressure) difference across a given lens of thickness L. Thus, the latter is important in determining the capability of a specific lens to meet the cornea oxygen demand. Generally, with the same lens material, the smaller the lens thickness the higher would be its dissolved oxygen transmissibility, DK/L.

As a conaequence of the combina~ion of the highly desirable tensile strength, elastic modulus, and high oxygen permeability properties of the instant materials, the resulting contact lenses may be advantageously fabricated e;ther as ultra thin contact lenses having an extremely high oxygen transmissibility in excess of the cornea oxygen demand for continuous wearing while still possessing remarkably superior mechanical strength, e.g. having a thickness between about 0.010 mm and about 0.1 mm, or alternatively, as relatively thick lenses while still possessing adequate oxygen transmissibility, e.g. having a thickness between about 0.2 mm and about Q.5 mm.

In addition9 the excellent optical clarity of the optionally crosslinked, annealed polyvinyl alcohol materials make them particularly suitable for use as soft contact lenses to provide good optical acuity and necessary visual correction for the patients.

Thus, the instant contact lenses can advantageously possess a lens thickness of between about 0.010 mm and about 0.5 mm. Ordinarily, for purposes of c~nvenience, the instant contact lens preferably possess a thickness between about 0.03 and 0.25 mm. The instant contact lens diameter can range between about 6 to 20 mm, preferably between about 8 to 16 mm.

~2~23~57 The instant optionally crosslinked annealed polyvinyl alcohol materials also exhibit superior elongation characteristics and elastic modulus as compared with poly-hydroxyethylmethacrylate.

The optionally crosslinked annealed polyvinyl alcohol materials possess increased resistance to visco-elastic deformation as compared to the non-annealed polyvinyl alcohol and are, consequently, substantially free of the so called "cold flow" or creep phenomens commonly exhibited in amorphous thermoplastic lens materials. ~s a result, they are resistant to permanent and significant deformation occasioned during eyelid motion or lens cleaning.

The optionally crosslinked annealed polyvinyl alcohol contact lenses contain, in their swollen use condition, between about 30 to 90 percent by weight water based upon the weight oE swollen material, preferably between about 45 to 85 percent by weight water.

The instant contact lenses can be advantageously prepared by various methods.

In one method, method A, the annealed optionally crosslinked, substantially shape-retaining contact lens is prepared by the steps comprising:

a) forming a lens blank from a substantially non-crosslinked polyvinyl alcohol resin having a weight average molecular weight of at least 6,000, in the presence or absence of a polyvinyl alcohol plasticizer;

b) annealing said lens blank un~er crystallinity promoting conditions to effectively increase the elastic modulus of the subsequently swollen contact lens~ such that the resulting annealed poly~inyl alcohol blank has a degree of crystallinity between about 0.195 and 0.70 based on the weight fraction of

2~7 crystalline material present in the polyvinyl alcohol polymer;

c) removing selected portions of said annealed blank until the remainder of the annealed blank constitutes a replica of said contact lens on a reduced scale; and d) swelling said annealed replica in an aqueous or nonaqueous swelling solvent, in the presence or absence of a chemical crosslinking agent, to obtain said substantially shape-retaining swollen contact lens, wherein said lens in its swollen equilibrium state with ocular tear fluid~ possesses sufficient oxygen transmissibility to meet the.needs of the human cornea.

In an alternate method, method B, the annealed optionally cross-linked substantially shape retaining contact lens is prepared.
by the steps comprisin~:

a) forming a replica of a contact.lens on a reduced scale in the form of a substantially non-crosslinked polyvinyl alcohol shape retaining polymer resin having a weight average molecular weight of at least 6,000 in the presence or absence of a polyvinyl alcohol plasticizer;

b) annealing said contact lens replica under crystallinity promoting conditions to effectively increase the elastic modulus of the subsequently swollen contact lens, such that the annealed contact lens replica has a degree of crystallinity between about 0.195 and 0.70 based on the weight fraction of crystalline material present in the polyvinyl a7cohol polymer; and c) swelling said annealed replica in an aqueous or nonaqueous swelling solvent, in the presence or absence of a chemical cross-linking agent, to obtain said substantially shape-retaining swollen contact lens, wherein said lens in its swollen equilibrium state with ocular tear fluid, possesses sufficient oxygen transmissibility to meet the needs of the human cornea.

Preferably, the amount of plasticizer when present, is present in an amount between about 0.01 and 30 percent by weight, based upon the total weight of plasticizer and polyvinyl alcohol, more preferably, between 0.01 and 15 percent by weight in methods A
and B.

Preferred plasticizers include polyols, such as ethylene glycol, propylene glycol, glycerol and ethylene glycol, mono- and di-methyl ether, tetrahydro~uran, formamide, dimethylacetamide, dimethylformamide and dimethylsulfoxide.

Most preferably, the plasticizer is glycerol or propylene glycol.

In either method A or method B, boric acid may be incorporated into the polyvinyl alcohol of step a) thereof. Thus, for example, the lens blank of step a) in method A may be prepared by casting an aqueous solution of the polyvinyl alcohol and boric acid into a film of a thickness greater than said lens replica, or by adding boric acid to molten polyvinyl alcohol and solidifying the resulting liquid mixture in the form of a lens blank. The lens replica of step a) in method B may similarly contain boric acid dissolved or dispersed therein. As the boric acid is not in the requisite tetra-valent state, crosslinking will not take place until the subsequent swelling step~ where crosslinking is effected by treat-me~t with an aqueous solution having a pH greater than 7.

Also where a polyol plasticizer is incorporated in the starting material of step ~ of method A or B, and the crosslinking agent ~2~:35i~

is a tetraval~nt metal salt or the like capable of reacting with the plasticizer, the plasticizer is removed, e.g. by washin~
with an aqueous solvent, prior to the crosslinking reaction.

In method A, the lens blank starting material of step a) can be formed by various techniques known per se. Thus, the lens blank can be'cut'from suitable rods, punched or stamped'out from polyvinyl alcohol sheets, or cast from molds, such as by melt extrusion, and the like.

In method B, the contact lens replica starting material in step a) therein may likewise be formed by various techniques known per se. For example, suitable lens replicas may be formed by lathing or cutting a solid uncrosslinked polyvinyl alcohol lens blank or the like; or by molding in a suitable mold in the molten state in the presence of a plasticizer; by spin drying an aqueous or aqueous/plasticizer solution of polyvinyl alcohol in a mold, analogous to known spin casting techniques~ or by compression molding of an optionally plasticized polyvinyl alcohol film.

As the artisan can appreciate, under crystallinity pro~oting conditions, step b) of method B may take place either simultaneously and/or subsequently to the formation of the lens replica formation of step a). For example, in spin drying, the lens replica polyvinyl alcohol polymer can be annealed in the spin mold under elevated temperature conditions and/or by controlled drying as set forth in the aforementioned A. Packter and M.S. Nerurkar article, and/or by pressurizing the system. Also, under compression molding of the lens replica in a suitable mold, the combination of pressure and elevated temperature for a time sufficient to substantially increase the crystallinity of the replica, may be used to obtain the desired annealed lens replica simultaneously with its formation. Alternatively, the steps of forming the lens replica and annealing the same under crystallinity promoting conditions may be done sequentially, by first forming the lens replica and then annealing the same.

The lens of the instant invention may be tinte~d if desired with suitable dyes and pigments, for cosmetic effects or for screening ou~ ultraviOlet light9 or for identification purposes3 by methods known, per se in the art. In one embodiment, the crosslinking agent itself may be a chromophore or form a chromophore under the crosslinking conditions. For example, vanadyl sulfate crosslinked polyvinyl alcohol yields a lightly blue tinted optically clear contact lens in the swollen state. Also an organic dye having two reactive groups capable of forming a covalently crosslinked polyvinyl alcohol may be used to form ~he tinted lens. Alternatively, the coloring material is a pigment, disperse dye or fiber-reactive dye as disclosed in EP~A-0072353.

It is understood that spherical, t~ric and polyfocal lenses, for use in the human eye, including bifocal contact lenses, having powers covering the ranges from about -20 to about +20 diopters can be advantageously prepared by methods A, and B, des-cribed supra. Thus, for example, the overall convex surface of the replicas in methods A and B may contain planar or concave regions ~here an overall negative diopter, or multiple diopters are desired.

It is further understood that the instant optionally crosslinked polyvinyl alcohol lenses are swollen with aqueous tear fluid under use conditions and this is taken into account in determining the configuration of the annealed lens replica. As a result, the con-figuration of the annealed lens replica is calculated based upon the extent of swelling which occurs subsequent to the lens replica step, e.g. upon subsequent aqueous treatment such as in the aqueous 3L2~:2~35~

medium or the aqueous or organic medium in which the optional crosslinking occurs. As the swollen lens is substantially uniform in op~ionally crosslinked polyvinyl alcohol density, said calculation is straghtforward and is dependent upon the percent of water present in the contact lens in their swollen use condition as compared to the amount of water present in the lens prior to swelling.

The contact lens of the instant invention may advantageously be stored for shipping in an isotonic solution having a pH of about 7, or if desired, in an aqueous borate solution.

The following examples are intended as only illustrative and are not indended to limit the nature or scope of the invention. All parts are by weight unless otherwise indicated.

Examples 1-21 illustrate methods of preparation of the soft contact lens system of the present invention.

Example 1 A polyvinyl alcohol film of 0.038 cm dry thickness containing 3.4 % glycerin as plasticizer was knife cast from an 18 % aqueous solution of ~LVANOL 71-30 (99-100 mole %
hydrolyzed polyvinyl alcohol with the weight-average and number-average molecular weights of 116,000 and 40,000 respectively, manufactured by DuPont~ initially containing 0.6 % glycerin and subsequently air dried for two days at 23C and 40 % relative humidity. The dried film contained residual water less than 5 %.

The transparent and thermoplastic polyvinyl alcohol film so formed was compressed at about 413-689 kPa on a laboratory press for a period of about 10 seconds at 180C between the two mold parts of a lens replica shaped mold to form and anneal the same. The concave part of the mold had a radius of curvature of 0.6 an cm ~ 2 ~92 ~ 5 7 - 20 ~

and the matching convex part had a radius of curvature of 0.635 cm.
The entire mold was prehea~ed to 180C beEore compression molding.
An annealed lens replica shaped article was thus formed and separated from the said film. The formed lens w~s then removed from the mold and cooled to room temperature.

Subsequently the formed lens was washed in distilled water over-night ~o remove the residual glycerin and swell the lens to its final use condition. The swollen lens was subsequently stored in isotonic saline solution. The lens so formed was soft9 resilient, optically clear and substantially resistant to tear and viscoelastic deformation with an equilibrium water content of 47.33 % by weight.

Example 2: Two compression molded polyviny] alcohol lenses containing -50 % and 70 % glycerine as plasticizer were prepared as described in Example 1 except that a molding temperature of 158C was used in both cases.

Afterwards, the molded annealed lens replicas were washed and swollen .. . . . . . .. . . . . ... . .. ..
in distilled water overnight removing the residual glycerin, and sub-sequently stored in istonic saline solution. The lenses so formed were soft, resilient, optically clear and substantially resistant to tear and viscoelastic deformation. The compositions of the lenses were tested for their dissolved oxygen permeabilities at 34C, the eye temperature, with the use of a polarographic sensor in an air saturated aqueous enviroment. These test results including the equilibrium water content values are presented in Table 1.

23~i7 Table 1 . .. ____ , ........... ~
Exa~ple No. Gl~cerin Equilibrium Water Dissolved O~ygen Content Content (%) permeability at 34C
(%~ ~xlO cm ~STP) cm L Cm2 sec cmHg ...... __ _ _ 2A 50 47.7 14.47 2B 70 53.6 22.9 . .____ ... _ .. _ Example 3: A 10 ~ aqueous polyvinyl alcohol solution containing 0.34 %
glycerin was prepared ~y dissolving appropriate amounts of elvanol 71-30 and glycerin in water at 100C. The resulting solution had a Brookfield viscosity about 1,500 mPaos at room temperature (23C).

About 40 mg of the said solution was charged into a glass mold having a spherical concave solid supporting surface with a radius of curvature of 0.5 cm. The mold, having a segment height of 0.4 c~
was then attached to a chuck and allowed to rotate about the axis transverse to the supporting surface at 350 revolutions per minute by the use of a variable speed moto. Such a spining process not only shaped the lens by centrifugal force but also generated a convection of ambient air to facilitate the drying of the said lens. After four hours of drying at 350 rpm, 23C and 40 % relative humidity, the lens shaped replica was dried to touch.

Afterwards, the dry lens together with the mold was annealed in an oven at 100C for one hour.~ Subsequently, the annealed lens replica was removed from the mold and washed in distilled water overnight to remove the residual glycerin and swell the lens to its final use condition. The swollen lens was then stored in iso-tonic saline solution. The lens so formed was soft, resilient, opticalle clear and substantially resistant to tear and viscoelastic diformation with an equilibrium water content of 67.26 % by weight.

xamples 4 - 9: Several thermally annealed polyvinyl alcohol lenses were prepared as described in E~ample 3. The swollen lenses, being washed free of glycerin, were then allowed to equilibrate in sodium borate solutions of cencentration up to 4 % to achieve a range of desired interal borate crosslinking concentrations.
The composition of each lens was tested for its dissolved oxygen permeability at 34C, the eye temperature, with the use of a polorographic sensor in an air saturated aqueous environment. The wet mechanical properties of the lens composition including tensile strength, elongation at break, and elastic modulus were determined on an Instron tester model 1123. These test results are summarized in Table 2.

3~

~, ~a ~ ~ ~ 0 00 . ~ ~
cq .. ____ _ _ _ ,,, , ~d P~
U~
~d ~ . . . .
~0 ~ ~ ~ O ~ ~ ~ O
O ~ ~ u~ a . ..". ~ ~0 ~J
~ a ~ . ,, ~o Q) ~ ~ O --~ o~ ~ 'I
E~ ~
.. _i_ . . ._ . s C~
B
o V~ U~ aJ U~
a ~E3 ~ ~ 00 0 1 0 .~
~ ~d oU c~ ~ ~ ~ ~ ,1 ,1 O ~ ~ ~q ~'0 I X
. _ ... .. ..
P~
~ ~ ~ ~ O
a~ ~ ~ ~ o~ ~ ~ ~ oO
~ o I~ o U~
C~ 'D t~
. _ _ h O ~1 ~ ~ ~ ~ O ,, ~ ~ O ~ ~, a~
h V 1~ ~)0 ~1 ~ CO
O t~ ~ \ O ~D O 0 O ~ ~ ,i ~ ~ ~ O
___ . ._ _.. __ Q~ O O J~
~ _ ~. _ ___ _ ~ ~ ~

~2~3~;7 The results of the tests shown in Table 2 illustrate the additional increase in tensile strength and elongation at break, as well as elastic modulus, coupled with high dissolved o~ygen permeability afforded by crosslinking of the instant thermally annealed polyvinyl alcohol contact lens materials especially in comparison with a conventional poly-HEMA contact lens material.

Examples 10-16_ A series of thermally annealed polyvinyl alcohol lenses were prepared as described in Example 3 except that no glycerin was added to the casting solution and annealing temperatures up to 125C were used to achieve a range of crystallinity and water swelling. The crystallinity (weight fraction of crystalline region) of each lens composition was evaluated from its dry density. ~he density was measured by weighing the samples in air and in heptane at 23C. The composition o each lens was also tested for its dissolved oxygen permeability and wet mechanical properties according to the procedures and conditions set forth in Examples

4-9. The test results are summarized in Table 3.

~2~;23~7 _ . , .~
C.IL~ ~
~ ~ ~ ~ ~ ~ ~ a~ I~ I`
~ ~ C~i C`l Lf) r~
.__ _ ~
u ~ o~ n ~
td ~ ~ ~ ~ n ~D o C~l ~ ~ ~ ~ ~

.~ __ h Q' co~^
~ ~ ~ ~ ~ ~ n ~ ~ ~:
L~ 1` 0 ~
~, ~ ~ ~ ~a ~J ~ cn o o~ ~ Lr~ o P~ cr. ~ r~ I~ ~ ~ ~
O ~_~ a~ ~~ ~ 1 ~ O oo n P ~ o ~
ol~ ~`
_. . _.. . .~

~D ~ O r~ CO a ~ ~ I~ ~ r~ CO
~1 .~ C~i O O ~ ~rl ` ~ ~ 00 00 ~ l O

_ ~ ~_ ___ n__ ___ --_ _ __ . ___ . ._ ~1 'r I ~ ~ ~ O ~ ~ O ~ r~
r ~ ~ 0 JJ ~I r~ ~ ~ ~ ~ ~ I
P~ S
____ ~
r~
~ O
rr~ J~J ~ _i r-l O 1~1 ~J O ~
C-d~ ~ ~C
' ~ O 11~ O O O U~ ~) g C~~ ~ O O O C`l O ~J
1_l r l 1_1 r l Q, _~ r~
_ ,_, __ __ . . ._._ ___ ~
~ .~ C ~ C ~ r~

2;~3~;i7 The results of the tests shown in Table 3 illustra~e the advantageous increase in tensile strength, elongation at break, and elastic modulus, coupled with high dissolved oxygen permeability afforded by the instant thermally annealed polyvinyl alcohol contact lens materials especially in comparison with a conventioanl poly-HEMA
contact lens material.

Example 17: A thermally annealed polyvinyl alcohol lens was prepared as described in ~xample 3 except that no glycerin was added to the casting solution and the annealing was done at 75C for 1 hour.
The swollen lens was then allowed to equilibrate in a 0.5 %
vanadyl sulfate solution with a 5 to 1, solution to polymer ratio to achieve the desired crosslinklng through complex for~ation. The lens so formed was soft, resilient, optically clear with blue tint, and substantially resistant to tear and viscoelastic deformation.
Such a lens composition exhibits a dissolved oxygen permeability of 55.52 x 10 [cm tSTP)cm/cm sec. cmHg] at 34C, a tensile strength of 30.4 N/cm an elongation at break of 296.5 %, and an elastic modùlus of 6.8 N/cm .

Examples 18-21: Four compression molded polyvinyl alcohol plano lenses con~aining 12.S % glycerin as plasticizer with a diameter of 13 mm and thickness of 0.115 mm were prepared according to the method described in Example 1. After washing and swelling in distilled water to remove the residual glycerin these lenses were then tinted on both sides by reacting each swollen lens in an aqueous mixture of 1 ml of a suitable reactive dye stock solution and 5 ml of a 10 % solution of sodium phosphate, tribasic dodeca-hydrate at room temperature (25C) for 1 hour. Afterwards, the tinted lenses were washed in distilled water to remove the residual reactants and subse~uently stored in pH 7.4 buffered isotonic saline. The reactive dyes used here were obtained under the trade name REMAZOL (Am. Hoechst Co.). They have the following general formula 22~
.

y S 2 C 2 C~2 S3Na The tinting reaction generally occurs at the ~-sulfatoethyls~lfonyl group which is a vinyl sulfone precursor.

The tinted lenses so obtained show permanent color fas~ with no extractables. The dye stocks used and the resulting light absorbance of the tinted lenses are summarized in Table 4.

Table 4 ~Exampl~ Tinted Dye Stock Solution Absorbance (Wavelength) No. Color (aqueous) 0.54% Remazol Black B 1.1 (600nm), 18 reen~ 0.54% Remazol Yellow GI 0.88(420nm) 19 Amber 2 % Remazol Golden Orange 36G 0.37(485nm) 20 Aquamari ~ 2.5~ Remazol Turquoise ~ 0.67(675nm) 21 Blue0.25% Remazol Black B 0.54(610n~)

Claims (13)

What is claimed is:
1. A process for preparing an optically clear soft contact lens of swollen solid polyvinyl alcohol having a weight average molecular weight of at least about 6,000, which has been annealed under crystallinity promoting conditions to a crystallinity degree between 0.195 to 0.7 and swollen in a swelling solvent, the resultant annealed, swollen lens possessing an oxygen transmissibilty capability in an aqueous environment in excess of that necessary to meet the needs of the human cornea by the steps comprising:

a) forming a lens blank from or forming a replica of a contact lens on a reduced scale in the form of a substantially non-crosslinked polyvinyl alcohol resin having a weight average molecular weight of at least 6,000, in the presence or absence of a polyvinyl alcohol plasticizer;

b) annealing said lens blank or said lens replica under crystalinity promoting conditions to effectively increase the elastic modulus of the subsequently swollen contact lens, such that the resulting annealed polyvinyl alcohol blank or said replica has a degree of crystallinity between about 0.195 and 0.70 based on the weight fraction of crystalline material present in the polyvinyl alcohol polymer;

c) removing selected portions of said annealed lens blank until the reaminder of the annealed blank constitutes a replica of said contact lens on a reduced scale; and d) swelling said annealed replica in an aqueous or nonaqueous swelling solvent, in the presence or absence of a chemical cross-linking agent, to obtain said substantially shape-retaining swollen contact lens, wherein said lens in its swollen equilibrium state with ocular tear fluid, possesses sufficient oxygen transmissibility to meet the needs of the human cornea.
2. A process according to claim 1, wherein step a) is conducted in the presence of about 0.01 to 70 % by weight plasticizer, based on the total weight of plasticizer and polyvinyl alcohol.
3. A process according to claim 2, wherein there is between about 0Ø and 30 percent by weight, based on the total weight of plasticizer and polyvinyl alcohol.
4. A process according to claim 1, wherein the plasticizer is glycerol or proplylene glycol.
5. A process according to claim 1, wherein the annealing step b) is conducted under thermal annealing conditions between about 45°C
and 200°C, in the presence of less than 20% by weight water.
6. A process according to claim 1, wherein the at least partially swollen annealed lens is sparingly crosslinked with a tetra-valent metal salt or an organic polyfunctional crosslinking agent.
7. A process according to claim 1, wherein the polyvinyl alcohol has a weight average molecular weight of at least about 10,000 and up to 1,000,000.
8. A process according to claim 1, wherein the polyvinyl alcohol contains less than 1 mole % of polyvinyl acetate units.
9. A process according to claim 1, wherein the polyvinyl alcohol, in its pre-annealed form, is substantially insoluble in water up to 50°C.
10. A process according to claim 6, which is sparingly crosslinked with a borate.
11. A process according to claim 10, wherein the milligrams of complexed boron per gram of polyvinyl alcohol is between about 0.5 to 50.
12. A process according to claim 1, the lens possessing a maximum thickness between about 0.010 mm and about 0.5 mm and a lens diameter between about 6 mm and 20 mm.
13. A process according to claim 1, wherein the bus contains in its swollen use condition between about 30 and 90 percent water based on the weight of swollen lens.
CA 426833 1982-04-29 1983-04-27 Annealed polyvinyl alcohol contact lens Expired CA1222357A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US37289382 true 1982-04-29 1982-04-29
US372,893 1982-04-29

Publications (1)

Publication Number Publication Date
CA1222357A true CA1222357A (en) 1987-06-02

Family

ID=23470055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 426833 Expired CA1222357A (en) 1982-04-29 1983-04-27 Annealed polyvinyl alcohol contact lens

Country Status (10)

Country Link
US (1) US4619793A (en)
JP (1) JPH0352842B2 (en)
KR (1) KR840004444A (en)
CA (1) CA1222357A (en)
DE (1) DE3365411D1 (en)
DK (1) DK191183D0 (en)
EP (1) EP0093944B1 (en)
ES (1) ES8403626A1 (en)
FI (1) FI831399L (en)
GB (1) GB2119957B (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5507805A (en) * 1982-05-03 1996-04-16 American Cyanamid Company Intraocular lens and method of retaining in place
NL8400339A (en) * 1984-02-03 1985-09-02 Tno A composition and method for preserving wood.
GB2163653B (en) * 1984-08-16 1988-05-18 Siepser Steven B Dry artificial intraocular lenses and method for their surgical implantation
US4598122A (en) * 1985-01-22 1986-07-01 Ciba-Geigy Corporation Polyoxirane crosslinked polyvinyl alcohol hydrogel contact lens
US4921884A (en) * 1987-02-26 1990-05-01 Minnesota Mining And Manufacturing Company Hydroxy-substituted polymeric shaped hydrogel article
JPS6323126A (en) * 1986-02-13 1988-01-30 Bio Material Yunibaasu:Kk Soft contact lens and its production
US4788007A (en) * 1986-11-28 1988-11-29 Baron Neville A Ophthalmic U.V. absorptive emollient
US4765977A (en) * 1986-11-28 1988-08-23 Baron Neville A Ophthalmic liquid sunglasses
US4978713A (en) * 1987-12-16 1990-12-18 Ciba-Geigy Corporation Polyvinyl alcohol derivatives containing pendant vinylic monomer reaction product units bound through ether groups and hydrogel contact lenses made therefrom
US5080924A (en) * 1989-04-24 1992-01-14 Drexel University Method of making biocompatible, surface modified materials
US5326584A (en) * 1989-04-24 1994-07-05 Drexel University Biocompatible, surface modified materials and method of making the same
US5174929A (en) * 1990-08-31 1992-12-29 Ciba-Geigy Corporation Preparation of stable polyvinyl alcohol hydrogel contact lens
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US5871679A (en) * 1991-04-10 1999-02-16 Isolyser Company, Inc. Method of producing hot water soluble garments and like fabrics
US5661217A (en) * 1994-08-05 1997-08-26 Isolyser Company, Inc. Method of manufacturing monolithic structures from polyvinyl alcohol
US5891812A (en) * 1996-10-11 1999-04-06 Isolyser Company, Inc. Liquid absorbable non-permeable fabrics and methods of making, using, and disposing thereof
CA2283407A1 (en) * 1997-03-14 1998-09-24 Exxon Research And Engineering Company Membranes comprising aminoalcohols in hydrophilic polymers
CA2307634C (en) * 1997-11-14 2008-02-05 Novartis Ag Methods and compositions for manufacturing tinted ophthalmic lenses
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6149842A (en) * 1998-11-12 2000-11-21 Novartis Ag Methods and compositions for manufacturing tinted ophthalmic lenses
US6846875B2 (en) * 2000-04-10 2005-01-25 Pharmacia Groningen Bv Hydrogels and methods for their production
US6770721B1 (en) 2000-11-02 2004-08-03 Surface Logix, Inc. Polymer gel contact masks and methods and molds for making same
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6774178B2 (en) 2001-01-05 2004-08-10 Novartis Ag Tinted, high Dk ophthalmic molding and a method for making same
DE60209180D1 (en) * 2001-01-24 2006-04-20 Novartis Ag A process for the production of lenses
WO2002078512A8 (en) 2001-04-02 2004-12-02 Therasense Inc Blood glucose tracking apparatus and methods
US6890075B2 (en) * 2001-05-30 2005-05-10 Novartis Ag Contact lens with PVA cover layer
US20030151825A1 (en) * 2001-12-28 2003-08-14 California Institute Of Technology Polyacrylate-based light adjustable optical element
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
JP4895822B2 (en) * 2004-01-13 2012-03-14 ポリマー サイエンシズ リミテッド Molding process
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US7399376B2 (en) * 2004-05-04 2008-07-15 Eastman Kodak Company Polarizing plate laminated with an improved glue composition and a method of manufacturing the same
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US7651596B2 (en) 2005-04-08 2010-01-26 Dexcom, Inc. Cellulosic-based interference domain for an analyte sensor
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US20070072977A1 (en) * 2005-09-27 2007-03-29 Taiwan Textile Research Institute Weather-resistant resin coating material and its manufacturing method
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
CA2636034A1 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care Inc. Medical device insertion
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7801582B2 (en) 2006-03-31 2010-09-21 Abbott Diabetes Care Inc. Analyte monitoring and management system and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
JP2010508091A (en) 2006-10-26 2010-03-18 アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. The method for detecting a decrease sensitivity of the analyte sensor in real time systems, and computer program products
US7781506B2 (en) 2007-01-26 2010-08-24 E.I. Du Pont De Nemours And Company Poly(vinyl alcohol) composition comprising a polyol
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US9204827B2 (en) 2007-04-14 2015-12-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US7768387B2 (en) * 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
EP2137637A4 (en) 2007-04-14 2012-06-20 Abbott Diabetes Care Inc Method and apparatus for providing data processing and control in medical communication system
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
EP2152350A4 (en) 2007-06-08 2013-03-27 Dexcom Inc Integrated medicament delivery device for use with continuous analyte sensor
CA2690870C (en) 2007-06-21 2017-07-11 Abbott Diabetes Care Inc. Health monitor
US8597188B2 (en) 2007-06-21 2013-12-03 Abbott Diabetes Care Inc. Health management devices and methods
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
CN101344600B (en) * 2007-07-13 2011-01-26 鸿富锦精密工业(深圳)有限公司;鸿海精密工业股份有限公司 Production method of plated film lens
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
WO2009085905A1 (en) * 2007-12-21 2009-07-09 Depuy Products Medical devices based on poly(vinyl alcohol)
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US8583205B2 (en) 2008-03-28 2013-11-12 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
EP2982383A1 (en) 2008-04-10 2016-02-10 Abbott Diabetes Care, Inc. Method for sterilizing an analyte sensor
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
WO2010009172A1 (en) 2008-07-14 2010-01-21 Abbott Diabetes Care Inc. Closed loop control system interface and methods
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US20100198034A1 (en) 2009-02-03 2010-08-05 Abbott Diabetes Care Inc. Compact On-Body Physiological Monitoring Devices and Methods Thereof
WO2010121084A1 (en) 2009-04-15 2010-10-21 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
EP2425209A4 (en) 2009-04-29 2013-01-09 Abbott Diabetes Care Inc Method and system for providing real time analyte sensor calibration with retrospective backfill
US8368556B2 (en) 2009-04-29 2013-02-05 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8613892B2 (en) 2009-06-30 2013-12-24 Abbott Diabetes Care Inc. Analyte meter with a moveable head and methods of using the same
CN104799866A (en) 2009-07-23 2015-07-29 雅培糖尿病护理公司 The analyte monitoring device
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
JP5622853B2 (en) * 2009-09-22 2014-10-03 クーパーヴィジョン インターナショナル ホウルディング カンパニー リミテッド パートナーシップ Hydrated hydrogel material used in ophthalmic applications and methods
EP2482720A4 (en) 2009-09-29 2014-04-23 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
WO2011053881A1 (en) 2009-10-30 2011-05-05 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
CA2766693A1 (en) 2010-03-24 2011-09-29 Abbott Diabetes Care Inc. Medical device inserters and processes of inserting and using medical devices
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
CN107019515A (en) 2011-02-28 2017-08-08 雅培糖尿病护理公司 Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
WO2013066873A1 (en) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
WO2013066849A1 (en) 2011-10-31 2013-05-10 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
EP2713879B1 (en) 2011-12-11 2017-07-26 Abbott Diabetes Care, Inc. Analyte sensor devices, connections, and methods
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US20150005602A1 (en) * 2013-06-28 2015-01-01 Google Inc Methods for Adhering a Substrate to a Polymer Layer
US9581551B2 (en) 2014-07-31 2017-02-28 Research & Business Foundation Sungkyunkwan University Color-change sensor using film for detecting harmful material

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA754452A (en) * 1967-03-14 Ceskoslovenska Akademie Ved Method for manufacturing soft, flexible contact lenses
US3193542A (en) * 1960-05-25 1965-07-06 Kurashiki Rayon Co Production of polyvinyl alcohol having improved characteristics
US3232916A (en) * 1962-04-17 1966-02-01 Eltra Corp Cross-linked membranes of polyvinyl alcohol
NL128305C (en) * 1963-09-11
US3548031A (en) * 1967-10-21 1970-12-15 Kuraray Co Shapable polyvinyl alcohol composition
US3679646A (en) * 1970-08-05 1972-07-25 Du Pont Preparation of polyvinyl alcohol having improved color properties by treating the polyvinyl ester with an alkali metal borohydride
JPS4935466A (en) * 1972-08-08 1974-04-02
JPS5324818B2 (en) * 1974-09-07 1978-07-22
NL188266C (en) * 1975-07-29 1992-05-18 Merck & Co Inc A process for the preparation of an ophthalmic implant.
JPS5443496A (en) * 1977-09-12 1979-04-06 Toshiba Corp Radar system
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4255475A (en) * 1979-03-22 1981-03-10 Delgrande Donald Mosaic structures
EP0077295A1 (en) * 1981-10-05 1983-04-20 Ciba-Geigy Ag Contact lenses of polyvinyl alcohol cross-linked by borate

Also Published As

Publication number Publication date Type
JP1690325C (en) grant
KR840004444A (en) 1984-10-15 application
ES521917D0 (en) grant
DK191183A (en) 1983-10-30 application
FI831399A0 (en) 1983-04-25 application
ES521917A0 (en) 1984-04-01 application
DK191183D0 (en) 1983-04-28 grant
EP0093944B1 (en) 1986-08-20 grant
FI831399L (en) 1983-10-30 grant
GB2119957B (en) 1985-10-09 grant
FI831399D0 (en) grant
GB8311253D0 (en) 1983-06-02 grant
ES8403626A1 (en) 1984-06-16 application
CA1222357A1 (en) grant
DE3365411D1 (en) 1986-09-25 grant
US4619793A (en) 1986-10-28 grant
JPS58214128A (en) 1983-12-13 application
EP0093944A2 (en) 1983-11-16 application
GB2119957A (en) 1983-11-23 application
FI831399A (en) application
EP0093944A3 (en) 1984-03-28 application
JPH0352842B2 (en) 1991-08-13 grant

Similar Documents

Publication Publication Date Title
US3700761A (en) Fabrication of soft plastic contact lens blank
US3503942A (en) Hydrophilic plastic contact lens
Hyon et al. Poly (vinyl alcohol) hydrogels as soft contact lens material
US4495313A (en) Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
US6310116B1 (en) Molded polymer article having a hydrophilic surface and process for producing the same
US5563184A (en) Macromonomers
US5849810A (en) Photocrosslinked polymers
US5505884A (en) Contact lenses and materials and methods of making same
US4347198A (en) Producing soft contact lenses
US4740533A (en) Wettable, flexible, oxygen permeable, substantially non-swellable contact lens containing block copolymer polysiloxane-polyoxyalkylene backbone units, and use thereof
US5486579A (en) Wettable silicone hydrogel compositions and methods for their manufacture
US4978713A (en) Polyvinyl alcohol derivatives containing pendant vinylic monomer reaction product units bound through ether groups and hydrogel contact lenses made therefrom
US4390676A (en) Ultraviolet absorbing lenses
US5135965A (en) Hydrogel-forming polymers used in intraocular lenses
US4670506A (en) Polyvinyl alcohol derivatives containing pendant (meth)acryloyl units bound through urethane groups and crosslinked hydrogel contact lenses made therefrom
US5292350A (en) Method for preparing tinted contact lens
US20050113549A1 (en) Crosslinkable polyurea prepolymers
US20060036052A1 (en) Low polydispersity poly-hema compositions
US6602930B2 (en) Materials for contact lenses comprising a macromer having the polysiloxane structure in the side chain
US4680336A (en) Method of forming shaped hydrogel articles
US4761069A (en) Contact lens and method of molding
US4064308A (en) Abrasion and antifog-resistant optical element
US5157093A (en) Hydroxyethyl cellulose derivatives containing pendant (meth)acryloyl units bound through urethane groups and hydrogel contact lenses made therefrom
US20060063852A1 (en) Silicone hydrogel contact lens
US5690953A (en) Polymeric ophthalmic lens with crosslinker containing saccharide residue

Legal Events

Date Code Title Description
MKEX Expiry